DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study

Gil Zalsman*, Amos Frisch, Shaul Lev-Ran, Andrés Martin, Elena Michaelovsky, Daniela Bensason, Doron Gothelf, Eitan Nahshoni, Samuel Tyano, Abraham Weizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalEuropean Neuropsychopharmacology
Volume13
Issue number3
DOIs
StatePublished - May 2003

Funding

FundersFunder number
Charles Smith Foundation9b-99
National Institute for Psychobiology in Israel

    Keywords

    • Adolescence
    • Dopamine
    • Pharmacogenetics
    • Polymorphism
    • Risperidone

    Fingerprint

    Dive into the research topics of 'DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study'. Together they form a unique fingerprint.

    Cite this